Compare AstraZeneca plc (AZN) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Prudential Financial Inc — how do they compare? AstraZeneca plc trades at $168.82 (market cap $253.13B), while Prudential Financial Inc trades at $114.7 (market cap $39.87B). The key difference: AstraZeneca plc is far larger — about 6.3× Prudential Financial Inc's market cap, and Prudential Financial Inc pays the higher dividend (4.88%). Which is the better fit depends on your goals.
| AZN | PRU | |
|---|---|---|
Market Cap | $253.13B | $39.87B |
Sector | Health | Financials |
52-Week High | $209.48 | $118.72 |
52-Week Low | $137.44 | $92.00 |
Enterprise Value | $279.37B | $66.92B |
Dividend Yield | 1.92% | 4.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
PRU trades at $116.17, up 0.69% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 11.96, net income margin of 5.5%, and recent earnings beats in Q3 2025 and Q1 2026. Recent news highlights dividend payments and expansion into India's life insurance market.
The outlook is mixed; solid profitability and low valuation support upside, but analyst consensus is cautious with a $102.50 price target below current levels. Key risks include volatile cash flows and high debt levels. Earnings on August 4, 2026, will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
